Functional inhibition of acetylcholine receptors by antibodies in myasthenic sera.
D000109:Acetylcholine / Q000378:metabolism; D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000918:Antibody Specificity; D001323:Autoantibodies / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology*; D001667:Binding, Competitive; D002038:Bungarotoxins / Q000378:metabolism; D002460:Cell Line; D006801:Humans; D007473:Ion Channels / Q000276:immunology; D051379:Mice; D009045:Motor Endplate / Q000187:drug effects / Q000502:physiology; D009132:Muscles / Q000166:cytology; D009157:Myasthenia Gravis / Q000097:blood / Q000276:immunology*; D051381:Rats; D011950:Receptors, Cholinergic / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000276:immunology* / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D014403:Tubocurarine / Q000378:metabolism; D064569:alpha7 Nicotinic Acetylcholine Receptor
D001323:Autoantibodies; D002038:Bungarotoxins; C579167:Chrna7 protein, human; C579166:Chrna7 protein, mouse; C579165:Chrna7 protein, rat; D007473:Ion Channels; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D012964:Sodium; D000109:Acetylcholine; D014403:Tubocurarine